{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:25:32Z","timestamp":1789205132962,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T00:00:00Z","timestamp":1440720000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme (GB)","doi-asserted-by":"publisher","award":["Project number 11\/07\/01"],"award-info":[{"award-number":["Project number 11\/07\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s40273-015-0318-3","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T05:50:42Z","timestamp":1440654642000},"page":"23-31","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene"],"prefix":"10.1007","volume":"34","author":[{"given":"Hedwig M.","family":"Blommestein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohan","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Worthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caro","family":"Noake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Riemsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Kleijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan L.","family":"Severens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiwenn J.","family":"Al","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,28]]},"reference":[{"key":"318_CR1","unstructured":"Guide to single technology appraisal process. London: NICE; 2009. Available at: http:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisals\/Guide-to-the-single-technology-appraisal-process.pdf . Accessed 30 March 2015."},{"key":"318_CR2","unstructured":"Myelodysplastic syndrome (deletion 5q)\u2014lenalidomide [ID480]. Available at: http:\/\/guidance.nice.org.uk\/TAG\/291 . Accessed 30 March 2015."},{"issue":"5","key":"318_CR3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40273-015-0257-z","volume":"33","author":"R Wade","year":"2015","unstructured":"Wade R, Duarte A, Simmonds M, Rodriguez-Lopez R, Duffy S, Woolacott N, et al. The clinical and cost effectiveness of aflibercept in combination with irinotecan and fluorouracil-based therapy (FOLFIRI) for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy: a critique of the evidence. Pharmacoeconomics. 2015;33(5):457\u201366.","journal-title":"Pharmacoeconomics."},{"issue":"8","key":"318_CR4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40273-015-0272-0","volume":"33","author":"M Stevenson","year":"2015","unstructured":"Stevenson M, Pandor A, Stevens JW, Rawdin A, Rice P, Thompson J, et al. Nalmefene for reducing alcohol consumption in people with alcohol dependence: an Evidence Review Group perspective of a nice single technology appraisal. Pharmacoeconomics. 2015;33(8):833\u2013847.","journal-title":"Pharmacoeconomics."},{"issue":"3","key":"318_CR5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40273-014-0233-z","volume":"33","author":"M Holmes","year":"2015","unstructured":"Holmes M, Davis S, Simpson E. Alteplase for the treatment of acute ischaemic stroke: a NICE single technology appraisal. An Evidence Review Group perspective. Pharmacoeconomics. 2015;33(3):225\u201333.","journal-title":"Pharmacoeconomics."},{"issue":"47","key":"318_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19470","volume":"19","author":"J Greenhalgh","year":"2015","unstructured":"Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Hockenhull J, et al. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. Health Technol Assess. 2015;19(47):1\u2013134.","journal-title":"Health Technol Assess"},{"issue":"12","key":"318_CR7","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40273-014-0189-z","volume":"32","author":"NR Latimer","year":"2014","unstructured":"Latimer NR, Carroll C, Wong R, Tappenden P, Venning MC, Luqmani R. Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal. Pharmacoeconomics. 2014;32(12):1171\u201383.","journal-title":"Pharmacoeconomics."},{"key":"318_CR8","doi-asserted-by":"crossref","unstructured":"Simpson EL, Davis S, Thokala P, Breeze PR, Bryden P, Wong R. Sipuleucel-T for the treatment of metastatic hormone-relapsed prostate cancer: a NICE single technology appraisal. An Evidence Review Group perspective. Pharmacoeconomics. 2015 [Epub ahead of print].","DOI":"10.1007\/s40273-015-0296-5"},{"key":"318_CR9","unstructured":"Understanding myelodysplastic syndromes: a patient handbook. 2008. Available at: www.mds-foundation.org\/pdf\/handbook-english.pdf . Accessed 30 March 2015."},{"key":"318_CR10","doi-asserted-by":"crossref","unstructured":"Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2002:136\u201361.","DOI":"10.1182\/asheducation-2002.1.136"},{"issue":"2","key":"318_CR11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.03907.x","volume":"120","author":"D Bowen","year":"2003","unstructured":"Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003;120(2):187\u2013200.","journal-title":"Br J Haematol"},{"key":"318_CR12","unstructured":"Health and Social Care Information Centre. Hospital episode statistics. Available at: http:\/\/www.hesonline.nhs.uk\/ . Accessed 30 March 2015."},{"issue":"10","key":"318_CR13","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/cncr.21860","volume":"106","author":"L Balducci","year":"2006","unstructured":"Balducci L. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer. 2006;106(10):2087\u201394.","journal-title":"Cancer"},{"key":"318_CR14","unstructured":"Committee for Medicinal Products for Human Use. Assessment report: revlimid. Procedure No. EMEA\/H\/C\/000717\/II\/0056. EMA\/297642\/2013. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000717\/WC500146340.pdf . Accessed 30 March 2015."},{"issue":"14","key":"318_CR15","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","volume":"118","author":"P Fenaux","year":"2011","unstructured":"Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-\/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765\u201376.","journal-title":"Blood"},{"key":"318_CR16","first-page":"464","volume":"30","author":"M Jaeger","year":"1992","unstructured":"Jaeger M, Aul C, Sohngen D, Germing U, Schneider W. Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes. Beitr Infusionsther. 1992;30:464\u20138.","journal-title":"Beitr Infusionsther."},{"issue":"3","key":"318_CR17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0955-3886(00)00089-8","volume":"23","author":"GJ Kontoghiorghes","year":"2000","unstructured":"Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus Sci. 2000;23(3):211\u201323.","journal-title":"Transfus Sci."},{"issue":"1","key":"318_CR18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.1365-2141.2001.03043.x","volume":"115","author":"A Wahlin","year":"2001","unstructured":"Wahlin A, Markevarn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol. 2001;115(1):25\u201333.","journal-title":"Br J Haematol"},{"key":"318_CR19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1477-7525-7-81","volume":"7","author":"A Szende","year":"2009","unstructured":"Szende A, Schaefer C, Goss TF, Heptinstall K, Knight R, Lubbert M, et al. Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health Qual Life Outcomes. 2009;7:81.","journal-title":"Health Qual Life Outcomes."},{"key":"318_CR20","unstructured":"Dolan SP, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey. The University of York. Discussion paper 138. 1995. http:\/\/www.york.ac.uk\/che\/pdf\/DP138.pdf . Accessed 5 March 2015."},{"issue":"30","key":"318_CR21","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","volume":"23","author":"L Malcovati","year":"2005","unstructured":"Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594\u2013603.","journal-title":"J Clin Oncol"},{"issue":"6","key":"318_CR22","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/leu.2011.391","volume":"26","author":"U Germing","year":"2012","unstructured":"Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia. 2012;26(6):1286\u201392.","journal-title":"Leukemia"},{"issue":"3","key":"318_CR23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223\u201332.","journal-title":"Lancet Oncol."},{"issue":"5","key":"318_CR24","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/leu.2012.369","volume":"27","author":"A Kuendgen","year":"2013","unstructured":"Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA, et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with low- or intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia. 2013;27(5):1072\u20139.","journal-title":"Leukemia"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-015-0318-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-015-0318-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-015-0318-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T13:12:40Z","timestamp":1551186760000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-015-0318-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,28]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1007\/s40273-015-0318-3","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,28]]}}}